- Home
- GSAT vs AKRO Comparison
GSAT vs AKRO Comparison
Compare GSAT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSAT
- AKRO
- Stock Information
- Founded
- GSAT 2003
- AKRO 2017
- Country
- GSAT United States
- AKRO United States
- Employees
- GSAT N/A
- AKRO N/A
- Industry
- GSAT Telecommunications Equipment
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- GSAT Consumer Discretionary
- AKRO Health Care
- Exchange
- GSAT Nasdaq
- AKRO Nasdaq
- Market Cap
- GSAT 5.7B
- AKRO 3.7B
- IPO Year
- GSAT 2006
- AKRO 2019
- Fundamental
- Price
- GSAT $51.48
- AKRO $54.04
- Analyst Decision
- GSAT Strong Buy
- AKRO Buy
- Analyst Count
- GSAT 4
- AKRO 10
- Target Price
- GSAT $49.00
- AKRO $73.56
- AVG Volume (30 Days)
- GSAT 1.4M
- AKRO 2.1M
- Earning Date
- GSAT 11-06-2025
- AKRO 11-07-2025
- Dividend Yield
- GSAT N/A
- AKRO N/A
- EPS Growth
- GSAT N/A
- AKRO N/A
- EPS
- GSAT N/A
- AKRO N/A
- Revenue
- GSAT $262,202,000.00
- AKRO N/A
- Revenue This Year
- GSAT $7.93
- AKRO N/A
- Revenue Next Year
- GSAT $10.71
- AKRO N/A
- P/E Ratio
- GSAT N/A
- AKRO N/A
- Revenue Growth
- GSAT 8.54
- AKRO N/A
- 52 Week Low
- GSAT $17.24
- AKRO $21.34
- 52 Week High
- GSAT $55.78
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- GSAT 59.38
- AKRO 67.29
- Support Level
- GSAT $46.50
- AKRO $53.90
- Resistance Level
- GSAT $51.56
- AKRO $54.31
- Average True Range (ATR)
- GSAT 4.45
- AKRO 0.23
- MACD
- GSAT 0.14
- AKRO -0.25
- Stochastic Oscillator
- GSAT 67.28
- AKRO 66.30
About GSAT Globalstar Inc.
Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services. Mobile satellite services are typically used by customers where existing terrestrial wireline and wireless communications networks are impaired or do not exist. The company provides communications services such as two-way voice and data transmission. In addition, one-way data transmission is also offered. Both services are offered using mobile or fixed devices. The company is an owner of satellite assets. It has one reportable segment: MSS business. The company generates the vast majority of its revenue within the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.